Company Encyclopedia
View More
name
SNSW
688117.SH
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. ChengDu ShengNuo Biotec Co.,Ltd.
3.047 T
688117.SHMarket value -Rank by Market Cap -/-

Financial Score

18/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking46/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE12.31%B
    • Profit Margin18.81%A
    • Gross Margin60.99%A
  • Growth ScoreA
    • Revenue YoY32.54%A
    • Net Profit YoY29.84%B
    • Total Assets YoY24.94%A
    • Net Assets YoY12.33%B
  • Cash ScoreB
    • Cash Flow Margin531.57%C
    • OCF YoY32.54%A
  • Operating ScoreC
    • Turnover0.37C
  • Debt ScoreC
    • Gearing Ratio45.95%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SNSW issued a profit warning, expecting a year-on-year increase of 100.53% in net profit attributable to the parent company for the first three quarters, reaching 145.10 million

    SNSW expects that the net profit attributable to the parent company in the first three quarters of 2025 will increase by 100.53% year-on-year to 145.10%, reaching between 114 million yuan and 140 million yuan. The company's main business is steadily developing, especially with the growing demand for orders in the peptide raw material business, which drives overall performance improvement and enhances market competitiveness and profitability

    Zhitong·
    SH
    688117
    -2.61%
    Zhitong·
    SH
    688117
    -2.61%

    SNSW: Shareholders Chuanfa Investment, Lu Changliang, and Wang Xiaoli plan to collectively reduce their holdings by no more than 3.43%

    SNSW announced that shareholder Chuanfa Investment plans to reduce its holdings by no more than 4,721,578 shares, accounting for 3% of the company's total share capital; Deputy General Manager Lu Changliang plans to reduce his holdings by no more than 96,579 shares, accounting for 0.0614% of the company's total share capital; Director and Deputy General Manager Wang Xiaoli plans to reduce her holdings by no more than 574,696 shares, accounting for 0.3652% of the company's total share capital. The reduction period is from September 15, 2025, to December 14, 2025

    Zhitong·
    SH
    688117
    -2.61%
    Zhitong·
    SH
    688117
    -2.61%

    SNSW released its semi-annual performance report, with a net profit attributable to the parent company of 88.96 million yuan, a year-on-year increase of 308.29%

    SNSW released its semi-annual report for 2025, with revenue of 338 million yuan, a year-on-year increase of 69.69%; net profit attributable to the parent company of 88.96 million yuan, a year-on-year increase of 308.29%; net profit excluding non-recurring gains and losses of 89.48 million yuan, a year-on-year increase of 367.92%; basic earnings per share of 0.57 yuan. The significant increase in net profit is mainly due to the increase in sales of active pharmaceutical ingredients, a decrease in R&D expenses, and a reduction in market business expenses

    Zhitong·
    SH
    688117
    -2.61%
    Zhitong·
    SH
    688117
    -2.61%

    SNSW: Acetate Ganirelix Injection has obtained a drug registration certificate

    According to the Zhitong Finance APP, SNSW announced that its wholly-owned subsidiary Chengdu SNSW Pharmaceutical Co., Ltd. recently received the "Drug Registration Certificate" issued by the National Medical Products Administration (referred to as "NMPA") for Acetate Ganirelix Injection. Acetate Ganirelix is used in women undergoing controlled ovarian stimulation (COS) protocols for assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges

    Zhitong·
    SH
    688117
    -2.61%
    Zhitong·
    SH
    688117
    -2.61%

    Hong Kong Stock Concept Tracking | New Commercial Insurance Innovative Drug Directory Added! 2025 Medical Insurance Directory Adjustment Starts, Will Innovative Drugs Welcome a Historic Turning Point? (Including Concept Stocks)

    China Post Securities stated that although innovative drugs may experience fluctuations in the short term, it holds an optimistic outlook on the market prospects for the next 2-3 years. Recently, the National Healthcare Security Administration released the adjustment plan for the 2025 catalog of innovative drugs for medical insurance and commercial health insurance, clearly supporting innovative drugs, especially the establishment of a commercial insurance catalog for innovative drugs for the first time, providing new payment avenues for high-value innovative drugs. The introduction of this policy combination has stimulated the market for innovative drugs and contributed to the improvement of a multi-level medication security system

    Zhitong·
    SH
    688117
    -2.61%
    HK
    01801
    +0.87%
    SH
    688076
    -0.44%
    Zhitong·
    SH
    688117
    -2.61%
    HK
    01801
    +0.87%
    SH
    688076
    -0.44%
    © 2025 Longbridge｜Disclaimer